Document:

EX-10.12

 Exhibit 10.12 

NGM BIOPHARMACEUTICALS, INC. 

EXECUTIVE EMPLOYMENT AGREEMENT 

for 
 Jeff Jonker 

This Executive Employment Agreement (“Agreement”) is effective as of November 17, 2014, by and between Jeff Jonker
(“Executive”) and NGM Biopharmaceuticals, Inc. (the “Company”). 
 WHEREAS, the
Company desires to employ Executive to provide personal services to the Company, and wishes to provide Executive with certain compensation and benefits in return for Executive’s services; and 

WHEREAS, Executive wishes to be employed by the Company and to provide personal services to the Company
in return for certain compensation and benefits. 
 NOW, THEREFORE, in consideration of
the mutual promises and covenants contained herein, it is hereby agreed by and between the parties hereto as follows: 
 1.
    Employment by the Company. 
 1.1     Position. Subject to terms and
conditions set forth herein, the Company agrees to employ Executive in the position of President, reporting to the Company’s Chief Executive Officer, and Executive hereby accepts such employment. During the term of Executive’s employment
with the Company, Executive will devote Executive’s best efforts and substantially all of Executive’s business time and attention to the business of the Company, except for approved vacation periods and reasonable periods of illness or
other incapacities permitted by the Company’s general employment policies. 
 1.2     Duties and
Location. Executive shall perform such duties as are consistent with the position of President. These duties will initially include responsibility for all aspects of the following operations of the Company: business and corporate development,
business strategy, human resources and legal (including intellectual property). The Board may modify Executive’s job title and duties, in a manner consistent with Executive’s training and experience, as it deems necessary and appropriate
in light of the Company’s needs and interests from time to time. Executive’s primary office location shall be the Company’s headquarters. The Company reserves the right to reasonably require Executive to perform Executive’s
duties at places other than Executive’s primary office location from time to time, and to require reasonable business travel. 

1.3     Policies and Procedures. The employment relationship between the parties shall be governed by the
general employment policies and practices of the Company, except that when the terms of this Agreement differ from, or are in conflict with, the Company’s general employment policies or practices, this Agreement shall control. 

2.     Compensation. 

2.1     Salary. For services to be rendered hereunder, Executive shall receive a base salary at the rate of
Three Hundred Seventy-Five Thousand Dollars ($375,000.00) per year (the “Base Salary”), subject to standard payroll deductions and withholdings and payable in accordance with the Company’s regular payroll schedule. 

2.2     Bonus. Executive will be entitled to participate in any bonus plan adopted by the Company for its
employees or executive officers on such terms as the Board may determine in its discretion. 

  
 1. 

 2.3     Standard Company Benefits. Executive shall be
entitled to all employee benefit programs for which Executive is eligible under the terms and conditions of the benefit plans that may be in effect from time to time and provided by the Company to its officers. 

2.4     Vacation. Executive will be entitled to three (3) weeks of paid vacation each year, such
vacation to be taken in accordance with the Company’s vacation policy (including, without limitation, its policy relating to maximum accrual). The timing and duration of specific vacations to be mutually and reasonably agreed to by the parties
hereto. 
 2.5     Expenses. The Company will reimburse Executive for reasonable travel, entertainment or
other expenses incurred by Executive in the furtherance of or in connection with the performance of Executive’s duties hereunder, in accordance with the Company’s expense reimbursement policy as in effect from time to time. 

2.6     Option Grant. Subject to the approval by the Board, Executive will be awarded a stock option to
purchase eight hundred fifty thousand (850,000) shares of the Company’s Common Stock (the “Option Grant”). The purchase price per share for the Option Grant will be the fair market value as determined by the Board when the Option
Grant is awarded. The Option Grant shall be subject to the terms and conditions of the Company’s 2008 Equity Incentive Plan, as amended (the “Plan”). On the first (1st) anniversary of Executive’s employment commencement date
(“Anniversary Date”), 1/4th of the shares subject to the Option Grant shall vest; thereafter 1/48th of the shares initially subject to the Option Grant shall vest on each month as measured from the Anniversary Date, provided in each case
(including on the Anniversary Date) that the Executive is then providing Continuous Service (as defined in the Plan) to the Company. 

3.     Proprietary Information Obligations. 

3.1     Proprietary Information Agreement. As a condition of employment, Executive agrees to execute and
abide by the Employee Proprietary Information and Inventions Agreement attached hereto as Exhibit A. 
 3.2
    Third-Party Agreements and Information. Executive represents and warrants that Executive’s employment by the Company will not conflict with any prior employment or consulting agreement or other agreement with
any third party, and that Executive will perform Executive’s duties to the Company without violating any such agreement. Executive represents and warrants that Executive does not possess confidential information arising out of prior employment,
consulting or other third party relationships, which would be used in connection with Executive’s employment by the Company, except as expressly authorized by that third party. During Executive’s employment by the Company, Executive will
use in the performance of Executive’s duties only information that is generally known and used by persons with training and experience comparable to Executive’s own, common knowledge in the industry, otherwise legally in the public domain
or obtained or developed by the Company or by Executive in the course of Executive’s work for the Company. 
 4.
    Outside Activities During Employment. 
 4.1
    Non-Company Business. With the exception of Executive providing strategic guidance on business and corporate development matters to Theravance Biopharma US, Inc. under the
existing consulting agreement between Executive and Theravance Biopharma US, Inc., or as otherwise agreed to in writing by the Executive and the Company’s Board of Directors in the future, Executive will not, during the term of Executive’s
employment with the Company, undertake or engage in any other employment, occupation or business enterprise, other than ones in which Executive is a passive investor. Executive may engage in civic and not-for-profit activities so long as such activities do not materially interfere with the performance of Executive’s duties hereunder. 

4.2     No Adverse Interests. Executive agrees not to acquire, assume or participate in, directly or
indirectly, any position, investment or interest known to be adverse or antagonistic to the Company, its business or prospects, financial or otherwise. 

  
 2. 

 5.     Termination of Employment 

5.1     At-Will Employment. Executive’s employment relationship
is at-will. Either Executive or the Company may terminate the employment relationship at any time, with or without Cause (as defined herein) or advance notice. 

5.2     Termination Without Cause or Resignation for Good Reason Following A Change In Control. If, on or
within eighteen (18) months after the effective date of a Change in Control (as defined herein), the Company terminates Executive’s employment without Cause (as defined herein) and other than as a result of his death or disability, or
Executive resigns for Good Reason (as defined herein), and provided such termination or resignation constitutes a “separation from service” (within the meaning of Treasury Regulation
Section 1.409A-l(h)), and Executive signs the Company’s standard form of release within the time period specified by the Company and allows it to become effective in accordance with its terms but in
no event later than 60 days following Executive’s termination, and provided Executive complies with Executive’s obligations under Executive’s Employee Proprietary Information and Inventions Agreement, then the Company shall provide
Executive with the following severance benefits: 
 (i)     Salary and Benefit Continuation. The Company
will pay Executive severance in the form of continuation of Executive’s Base Salary (at the rate then in effect) for a nine (9) month period following Executive’s last day of employment, in addition to any accrued salary, the accrued
but unpaid portion of Executive’s bonus, if any, and accrued and unused vacation, through Executive’s last day of employment. These salary continuation payments will be paid on the Company’s regular payroll schedule and subject to
standard deductions and withholdings over the applicable period following termination; provided, however, that no payments will be made prior to the 60th day following Executive’s termination. On the 60th day following Executive’s
termination date, the Company will pay Executive in a lump sum the salary continuation payments that Executive would have received on or prior to such date under the original schedule but for the delay while waiting for the release deadline, with
the balance of the cash severance being paid as originally scheduled. Each such installment will be deemed a separate “payment” for purposes of Section 409A of the Code. In addition, Executive shall have the right to continue his
health insurance benefits pursuant to the Consolidated Omnibus Budget Reconciliation Act of 1985 (“COBRA”) or successor statute and any analogous provisions of applicable state law. Provided that Executive makes a timely and accurate
election for continued health insurance coverage (including medical, dental, vision and prescription) under COBRA (or any state law of similar effect), the Company will pay the premiums for such continued coverage for Executive and his eligible
dependents for the first nine (9) months of such coverage, or such earlier date as Executive (or his dependents, as applicable) ceases to be eligible for such continuation coverage. 

(ii)     Accelerated Vesting. The Company will accelerate the vesting of the Stock Rights, to the extent
then-outstanding and unvested, such that all shares subject to the Stock Rights shall be deemed immediately vested and exerciseable as of Executive’s termination date. 

5.3     Termination Without Cause or Resignation for Good Reason Not Following A Change In Control. If at
any time other than on or within eighteen (18) months following the effective date of a Change in Control, the Company terminates Executive’s employment without Cause or Executive resigns for Good Reason, then Executive will not be
entitled to any further compensation from the Company (other than accrued salary, and accrued and unused vacation, through Executive’s last day of employment), including severance pay, pay in lieu of notice or any other such compensation. 

5.4     Termination for Cause; Resignation Without Good Reason. If at any time, the Company terminates
Executive’s employment with the Company for Cause, or Executive resigns without Good 

  
 3. 

 
Reason, then Executive will not be entitled to any further compensation from the Company (other than accrued salary, the accrued but unpaid portion of Executive’s bonus, if any, and accrued
and unused vacation, through Executive’s last day of employment), including severance pay, pay in lieu of notice or any other such compensation. 

5.5     Section 409A Compliance. It is intended that each installment of the severance payments and benefits
provided for in this Agreement is a separate “payment” for purposes of Section 409A. For the avoidance of doubt, it is intended that the severance satisfies, to the greatest extent possible, the exemptions from the application of
Section 409A provided under Treasury Regulation 1.409A-l(b)(4) and 1.409A-l(b)(9). Notwithstanding the foregoing, if the Company (or, if applicable, the successor
entity thereto) determines that the severance payment provided above upon a separation from service constitute “deferred compensation” under Section 409A of the Internal Revenue Code (together, with any state law of similar effect,
“Section 409A”) and if Executive is a “specified employee” of the Company or any successor entity thereto as of the separation from service, as such term is defined in Section 409A(a)(2)(B)(i) (a “Specified
Employee”), then, solely to the extent necessary to avoid the incurrence of the adverse personal tax consequences under Section 409A, the timing of the severance (or any portion thereof) shall be delayed as follows: on the earlier to occur
of (i) the date that is six months and one day after the date of separation of service or (ii) the date of Executive’s death (such earlier date, the “Delayed Initial Payment Date”), the Company (or the successor entity
thereto, as applicable) shall (A) pay to Executive a lump sum amount equal to the sum of the severance payments that Executive would otherwise have received through the Delayed Initial Payment Date if the commencement of the payment of the
severance had not been delayed pursuant to this paragraph and (B) commence paying the balance of the severance in accordance with the payment schedule set forth above. 

5.6     Definitions. 

(i)     Cause. For purposes of this Agreement, “Cause” shall mean the good faith determination by
the Board that any one or more of the following events has occurred: (a) conviction of any felony or any crime involving moral turpitude or dishonesty; (b) participation in a fraud or act of dishonesty against the Company; (c) willful
and material breach of Executive’s duties that has not been cured within 30 days after written notice from the Board of such breach; (d) intentional and material damage to the Company’s property; (e) material breach of the
Proprietary Information and Inventions Agreement; or (f) death, severe physical or mental disability. 
 (ii)
    Change in Control. For purposes of this Agreement, a “Change in Control” shall mean: (a) a sale of substantially all of the assets of the Company; (b) a merger or consolidation in which the
Company is not the surviving corporation (other than a merger or consolidation in which stockholders immediately before the merger or consolidation have, immediately after the merger or consolidation, a majority of the voting power of the surviving
corporation); (c) a reverse merger in which the Company is the surviving corporation but the shares of the Company’s Common Stock outstanding immediately preceding the merger are converted by virtue of the merger into other property, whether in
the form of securities, cash or otherwise (other than a reverse merger in which stockholders immediately before the merger have, immediately after the merger, a majority of the voting power of the surviving corporation); or (d) any transaction
or series of related transactions in which 50% or more of the Company’s voting power is transferred, other than the sale by the Company of stock in transactions the primary purpose of which is to raise capital for the Company’s operations
and activities. 
 (iii)     Code. For purposes of this Agreement, “Code” shall mean the
Internal Revenue Code of 1986, as amended 
 (iv)     Good Reason. For purposes of this Agreement,
Executive shall have “Good Reason” for Executive’s resignation from all positions held with the Company if any of the following actions are taken by the Company or a successor corporation or entity without Executive’s consent,
and Executive notifies the Company in writing, within ten (10) days after the occurrence of one of the following actions, that Executive intends 

  
 4. 

 
to terminate his employment no earlier than thirty (30) days after providing such notice, and the Company fails to cure such actions within thirty (30) days after receipt of such
notice, and such resignation is effective not later than (30) days after the Company fails to cure the issue: (a) a substantial reduction of Executive’s rate of compensation; (b) a material reduction in Executive’s duties or
responsibilities; (c) a material failure or refusal of a successor to the Company to assume the Company’s obligations under this Agreement in the event of a Change in Control; or (d) a relocation of Executive’s principal place of
employment to a place greater than 50 miles from Executive’s then current principal place of employment, which relocation results in a material increase in Executive’s commute. 

(v)     Stock Rights. For purposes of this Agreement, “Stock Rights” shall mean all of
Executive’s options, restricted stock, restricted stock units or rights to acquire vested ownership of shares of Common Stock of the Company under plans, agreements or arrangements that are compensatory in nature, including, without limitation,
the Option Grant, the Plan and other agreements between the Company and Executive. 
 6.     General Provisions.

 6.1     Notices. Any notices provided must be in writing and will be deemed effective upon the
earlier of personal delivery (including personal delivery by fax) or the next day after sending by overnight carrier, to the Company at its primary office location and to Executive at the address as listed on the Company payroll. 

6.2     Severability. Whenever possible, each provision of this Agreement will be interpreted in such manner
as to be effective and valid under applicable law, but if any provision of this Agreement is held to be invalid, illegal or unenforceable in any respect under any applicable law or rule in any jurisdiction, such invalidity, illegality or
unenforceability will not affect any other provision or any other jurisdiction, but this Agreement will be reformed, construed and enforced in such jurisdiction to the extent possible in keeping with the intent of the parties. 

6.3     Waiver. Any waiver of any breach of any provisions of this Agreement must be in writing to be
effective, and it shall not thereby be deemed to have waived any preceding or succeeding breach of the same or any other provision of this Agreement. 

6.4     Complete Agreement. This Agreement, including Exhibit A, between Executive and the Company
constitutes the entire agreement between Executive and the Company and it is the complete, final and exclusive embodiment of their agreement with regard to this subject matter. It is entered into without reliance on any promise or representation
other than those expressly contained herein, and it cannot be modified or amended except in a writing signed by a duly authorized officer of the Company. 

6.5     Counterparts. This Agreement may be executed in separate counterparts, any one of which need not
contain signatures of more than one party, but all of which taken together will constitute one and the same Agreement. 
 6.6
    Headings. The headings of the sections hereof are inserted for convenience only and shall not be deemed to constitute a part hereof nor to affect the meaning thereof 

6.7     Successors and Assigns. This Agreement is intended to bind and inure to the benefit of and be
enforceable by Executive and the Company, and their respective successors, assigns, heirs, executors and administrators, except that Executive may not assign any of his duties hereunder and he may not assign any of his rights hereunder without the
written consent of the Company, which shall not be withheld unreasonably. 
 6.8     Choice of Law. All
questions concerning the construction, validity and interpretation of this Agreement will be governed by the law of the State of California. 

6.9     Authorization. Executive’s employment with the Company shall be contingent upon
Executive’s providing legal proof of Executive’s identity and authorization to work in the United States. 

  
 5. 

 IN WITNESS WHEREOF, the
parties have executed this Agreement on the day and year first written above. 
  

	
	NGM BIOPHARMACEUTICALS, INC.
	
	 /s/ William J. Rieflin

	William J. Rieflin
	Chief Executive Officer
	
	EXECUTIVE
	
	 /s/ Jeff Jonker

	Jeff Jonker

  
 6. 

 EMPLOYEE CONFIDENTIAL INFORMATION AND INVENTIONS ASSIGNMENT AGREEMENT 

In consideration of my employment or continued employment by NGM Biopharmaceuticals, Inc. (“Company”), and the compensation
paid to me now and during my employment with the Company, I agree to the terms of this Agreement as follows: 

 

 1.    CONFIDENTIAL INFORMATION PROTECTIONS.

 1.1    Nondisclosure; Recognition of Company’s Rights. At all times during and after my
employment, I will hold in confidence and will not disclose, use, lecture upon, or publish any of Company’s Confidential Information (defined below), except as may be required in connection with my work for Company, or as expressly authorized
by the Chief Executive Officer (the “CEO”) of Company. I will obtain the CEO’s written approval before publishing or submitting for publication any material (written, oral, or otherwise) that relates to my work at Company
and/or incorporates any Confidential Information. I hereby assign to Company any rights I may have or acquire in any and all Confidential Information and recognize that all Confidential Information shall be the sole and exclusive property of Company
and its assigns. 
 1.2    Confidential Information. The term “Confidential
Information” shall mean any and all confidential knowledge, data or information related to Company’s business or its actual or demonstrably anticipated research or development, including without limitation (a) trade secrets,
inventions, ideas, processes, computer source and object code, data, formulae, programs, other works of authorship, know-how, improvements, discoveries, developments, designs, and techniques;
(b) information regarding products, services, plans for research and development, marketing and business plans, budgets, financial statements, contracts, prices, suppliers, and customers; (c) information regarding the skills and
compensation of Company’s employees, contractors, and any other service providers of Company; and (d) the existence of any business discussions, negotiations, or agreements between Company and any third party. 

1.3    Third Party Information. I understand that Company has received and in the future will receive from
third parties confidential or proprietary information (“Third Party Information”) subject to a duty on Company’s part to maintain the confidentiality of such information and to use it only for certain limited purposes. During
and after the term of my employment, I will hold Third Party Information in strict confidence and will not disclose to anyone (other than Company personnel who need to know such information in connection with their work for Company) or use, Third
Party Information, except in connection with my work for Company or unless expressly authorized by an officer of Company in writing. 

1.4    No Improper Use of Information of Prior Employers and Others. I represent that my employment by
Company does not and will not breach any agreement with any former employer, including any noncompete agreement or any agreement to keep in confidence or refrain from using information acquired by me prior to my employment by Company. I further
represent that I have not entered into, and

 
will not enter into, any agreement, either written or oral, in conflict with my obligations under this Agreement. During my employment by Company, I will not improperly make use of, or disclose,
any information or trade secrets of any former employer or other third party, nor will I bring onto the premises of Company or use any unpublished documents or any property belonging to any former employer or other third party, in violation of any
lawful agreements with that former employer or third party. I will use in the performance of my duties only information that is generally known and used by persons with training and experience comparable to my own, is common knowledge in the
industry or otherwise legally in the public domain, or is otherwise provided or developed by Company. 

2.    INVENTIONS. 

2.1    Inventions and Intellectual Property Rights. As used in this Agreement, the term
“Invention” means any ideas, concepts, information, materials, processes, data, programs, know-how, improvements, discoveries, developments, designs, artwork, formulae, other copyrightable
works, and techniques and all Intellectual Property Rights in any of the items listed above. The term “Intellectual Property Rights” means all trade secrets, copyrights, trademarks, mask work rights, patents and other intellectual
property rights recognized by the laws of any jurisdiction or country. 
 2.2    Prior Inventions. I
have disclosed on Exhibit A a complete list of all Inventions that (a) I have, or I have caused to be, alone or jointly with others, conceived, developed, or reduced to practice prior to the commencement of my employment by
Company; (b) in which I have an ownership interest or which I have a license to use; (c) and that I wish to have excluded from the scope of this Agreement (collectively referred to as “Prior Inventions”). If no Prior
Inventions are listed in Exhibit A, I warrant that there are no Prior Inventions. I agree that I will not incorporate, or permit to be incorporated, Prior Inventions in any Company Inventions (defined below) without Company’s prior
written consent. If, in the course of my employment with Company, I incorporate a Prior Invention into a Company process, machine or other work, I hereby grant Company a non-exclusive, perpetual, fully-paid
and royalty-free, irrevocable and worldwide license, with rights to sublicense through multiple levels of sublicensees, to reproduce, make derivative works of, distribute, publicly perform, and publicly display in any form or medium, whether now
known or later developed, make, have made, use, sell, import, offer for sale, and exercise any and all present or future rights in, such Prior Invention. 

2.3    Assignment of Company Inventions. Inventions assigned to the Company or to a third party as
directed by the Company pursuant to the section titled “Government or Third Party” are referred to in this Agreement

 

  
 7. 

 
as “Company Inventions.” Subject to the section titled “Government or Third Party” and except for Inventions that I can prove qualify fully under the provisions of
California Labor Code section 2870 and I have set forth in Exhibit A, I hereby assign and agree to assign in the future (when any such Inventions or Intellectual Property Rights are first reduced to practice or first fixed in a tangible
medium, as applicable) to Company all my right, title, and interest in and to any and all Inventions (and all Intellectual Property Rights with respect thereto) made, conceived, reduced to practice, or learned by me, either alone or with others,
during the period of my employment by Company. 
 2.4    Obligation to Keep Company Informed. During the
period of my employment and for one (1) year after my employment ends, I will promptly and fully disclose to Company in writing (a) all Inventions authored, conceived, or reduced to practice by me, either alone or with others, including
any that might be covered under California Labor Code section 2870, and (b) all patent applications filed by me or in which I am named as an inventor or co-inventor. 

2.5    Government or Third Party. I agree that, as directed by the Company, I will assign to a third
party, including without limitation the United States, all my right, title, and interest in and to any particular Company Invention. 

2.6    Enforcement of Intellectual Property Rights and Assistance. During and after the period of my
employment, I will assist Company in every proper way to obtain and enforce United States and foreign Intellectual Property Rights relating to Company Inventions in all countries. If the Company is unable to secure my signature on any document
needed in connection with such purposes, I hereby irrevocably designate and appoint Company and its duly authorized officers and agents as my agent and attorney in fact, which appointment is coupled with an interest, to act on my behalf to execute
and file any such documents and to do all other lawfully permitted acts to further such purposes with the same legal force and effect as if executed by me. 

2.7    Incorporation of Software Code. I agree that I will not incorporate into any Company software or
otherwise deliver to Company any software code licensed under the GNU General Public License or Lesser General Public License or any other license that, by its terms, requires or conditions the use or distribution of such code on the disclosure,
licensing, or distribution of any source code owned or licensed by Company. 
 3.    RECORDS. I agree to
keep and maintain adequate and current records (in the form of notes, sketches, drawings and in any other form that is required by the Company) of all Inventions made by me during the period of my employment by the Company, which records shall be
available to, and remain the sole property of, the Company at all times. 
 4.    ADDITIONAL
ACTIVITIES. I agree that (a) during the term of my employment by Company, I will not, without

 
Company’s express written consent, engage in any employment or business activity that is competitive with, or would otherwise conflict with my employment by, Company, and (b) for the
period of my employment by Company and for one (l) year thereafter, I will not, either directly or indirectly, solicit or attempt to solicit any employee, independent contractor, or consultant of Company to terminate his, her or its
relationship with Company in order to become an employee, consultant, or independent contractor to or for any other person or entity. 

5.    RETURN OF COMPANY PROPERTY. Upon termination of my
employment or upon Company’s request at any other time, I will deliver to Company all of Company’s property, equipment, and documents, together with all copies thereof, and any other material containing or disclosing any Inventions, Third
Party Information or Confidential Information and certify in writing that I have fully complied with the foregoing obligation. I agree that I will not copy, delete, or alter any information contained upon my Company computer or Company equipment
before I return it to Company. In addition, if I have used any personal computer, server, or e-mail system to receive, store, review, prepare or transmit any Company information, including but not limited to,
Confidential Information, I agree to provide the Company with a computer-useable copy of all such Confidential Information and then permanently delete and expunge such Confidential Information from those systems; and I agree to provide the Company
access to my system as reasonably requested to verify that the necessary copying and/or deletion is completed. I further agree that any property situated on Company’s premises and owned by Company is subject to inspection by Company’s
personnel at any time with or without notice. Prior to the termination of my employment or promptly after termination of my employment, I will cooperate with Company in attending an exit interview and certify in writing that I have complied with the
requirements of this section. 
 6.    NOTIFICATION OF NEW
EMPLOYER. If I leave the employ of Company, I consent to the notification of my new employer of my rights and obligations under this Agreement, by Company providing a copy of this Agreement or
otherwise. 
 7.    GENERAL PROVISIONS. 

7.1    Governing Law and Venue. This Agreement and any action related thereto will be governed and
interpreted by and under the laws of the State of California, without giving effect to any conflicts of laws principles that require the application of the law of a different state. I expressly consent to personal jurisdiction and venue in the state
and federal courts for the county in which Company’s principal place of business is located for any lawsuit filed there against me by Company arising from or related to this Agreement. 

7.2    Severability. If any provision of this Agreement is, for any reason, held to be invalid or
unenforceable, the other provisions of this Agreement will remain enforceable and the invalid or unenforceable provision will be deemed modified so that it is valid and enforceable to the maximum extent permitted by law.

 

  
 8. 

 
 7.3    Survival. This Agreement shall survive the
termination of my employment and the assignment of this Agreement by Company to any successor or other assignee and be binding upon my heirs and legal representatives. 

7.4    Employment. I agree and understand that nothing in this Agreement shall give me any right to
continued employment by Company, and it will not interfere in any way with my right or Company’s right to terminate my employment at any time, with or without cause and with or without advance notice. 

7.5    Notices. Each party must deliver all notices or other communications required or permitted under
this Agreement in writing to the other party at the address listed on the signature page, by courier, by certified or registered mail (postage prepaid and return receipt requested), or by a nationally-recognized express mail service. Notice will be
effective upon receipt or refusal of delivery. If delivered by certified or registered mail, notice will be considered to have been given five (5) business days after it was mailed, as evidenced by the postmark. If delivered by courier or
express mail service, notice will be considered to have been given on the delivery date reflected by the courier or express mail service receipt. Each party may change its address for receipt of notice by giving notice of the change to the other
party. 
 7.6    Injunctive Relief. I acknowledge that, because my services are personal and unique and
because I will have access to the Confidential Information of Company, any breach of this Agreement by me would cause irreparable injury to Company for which monetary damages would not be an

 
adequate remedy and, therefore, will entitle Company to injunctive relief (including specific performance). The rights and remedies provided to each party in this Agreement are cumulative and in
addition to any other rights and remedies available to such party at law or in equity. 
 7.7    Waiver.
Any waiver or failure to enforce any provision of this Agreement on one occasion will not be deemed a waiver of that provision or any other provision on any other occasion. 

7.8    Export. I agree not to export, directly or indirectly, any U.S. technical data acquired from
Company or any products utilizing such data, to countries outside the United States, because such export could be in violation of the United States export laws or regulations. 

7.9    Entire Agreement. If no other agreement governs nondisclosure and assignment of inventions during
any period in which I was previously employed or am in the future employed by Company as an independent contractor, the obligations pursuant to sections of this Agreement titled “Confidential Information Protections” and
“Inventions” shall apply. This Agreement is the final, complete and exclusive agreement of the parties with respect to the subject matter hereof and supersedes and merges all prior communications between us with respect to such matters. No
modification of or amendment to this Agreement, or any waiver of any rights under this Agreement, will be effective unless in writing and signed by me and the CEO of Company. Any subsequent change or changes in my duties, salary or compensation will
not affect the validity or scope of this Agreement. 

 

  
 This Agreement shall be
effective as of the first day of my employment with Company. 
  

									
	EMPLOYEE: 	 		 	COMPANY:
			
	I HAVE READ, UNDERSTAND, AND ACCEPT THIS AGREEMENT AND HAVE BEEN
GIVEN THE OPPORTUNITY TO REVIEW IT WITH INDEPENDENT LEGAL COUNSEL.	 		 	ACCEPTED AND AGREED:
			
	 /s/ Jeff Jonker
	 		 	 /s/ William J. Rieflin

	(Signature)	 		 	(Signature)

  

									
	By:	  	Jeff Jonker	 		 	By:	 	William J. Rieflin

									
					
	Title:	  	President	 		 	Title:	 	CEO

									
					
	Date:	  	11/17/14	 		 	Date:	 	11/17/14

									
					
	Address:	  		 		 	Address:	 	 630 Gateway Boulevard
 South San Francisco, CA
94080-7014

  
 9. 

 EXHIBIT A 

INVENTIONS 

1.    Prior Inventions Disclosure. The following is a complete list of all Prior Inventions (as provided in Section 2.2
of the attached Employee Confidential Information and Inventions Assignment Agreement, defined herein as the “Agreement”): 
  

					
	☑    None	  		  	
			
	☐    See immediately below:	  		  	
	
	  

	
	  

 2.    Limited Exclusion Notification. 

THIS IS TO NOTIFY you in accordance with Section 2872 of the
California Labor Code that the foregoing Agreement between you and Company does not require you to assign or offer to assign to Company any Invention that you develop entirely on your own time without using Company’s equipment, supplies,
facilities or trade secret information, except for those Inventions that either: 
 a.    Relate at the time of
conception or reduction to practice to Company’s business, or actual or demonstrably anticipated research or development; or 

b.    Result from any work performed by you for Company. 

To the extent a provision in the foregoing Agreement purports to require you to assign an Invention otherwise excluded from the preceding
paragraph, the provision is against the public policy of this state and is unenforceable. 
 This limited exclusion does not apply to any
patent or Invention covered by a contract between Company and the United States or any of its agencies requiring full title to such patent or Invention to be in the United States. 

  
 10.EX-10.13

 Exhibit 10.13 

NGM BIOPHARMACEUTICALS, INC. 
 April 28, 2011 

Aetna W. Wun, Ph.D. 
 Dear Aetna: 

On behalf of NGM Biopharmaceuticals, Inc. (“NGM” or the “Company”), I am pleased to invite you to join the Company as Executive Director,
Business Development, reporting to Helen Kim and me. In this position, you will be responsible for working with Helen to lead the business development group of the Company. These responsibilities will include managing relationships with various
prospective pharmaceutical partners, advancing discussions regarding potential partnerships and supervising the corporate development, strategy and grants functions. We believe this offer represents an extraordinary opportunity, and we look forward
to the possibility of your joining our exceptional team. 
 Below are details of the compensation and benefits program we are offering as part of your
employment with NGM, as well as other terms of your employment. Should you have any questions regarding any part of this offer, or wish to receive additional details, please let us know. Your annual base salary will be $225,000.00, less payroll
deductions and all required withholdings, paid bi-weekly over 26 pay periods per year. In addition, you will be eligible to receive a one-time payment of $65,000.00
within the first two pay periods of your employment with NGM. Should you voluntarily resign from NGM within two (2) years from your start date, you will be required to repay the pro-rated portion of this
payment based on the number of months you were employed by the Company prior to your resignation. 
 Your start date will be as soon as practicable
following the selection and training of your successor, with a present expectation that you would join NGM on or around September 2, 2011. You agree to structure your departure in a fashion that minimizes the repayment of relocation
reimbursements previously made to you by your current employer. The precise start date will established as soon as practicable following your acceptance of this offer. 

NGM provides all eligible employees with a comprehensive benefits program. You will have the opportunity to participate in these benefits, which include
medical, dental and vision coverage for you and your eligible dependents, if you choose to enroll them. In addition, we provide life insurance, LTD and AD&D coverage, along with a comprehensive 401(k) program. NGM also provides benefits
including Company holidays, vacation, sick leave and Health Care and Dependent Flexible Spending Accounts. The Company may change compensation and benefits from time to time in its discretion. There is a formal performance review period once a year.

 An important component of your compensation includes the opportunity for ownership in the Company. After you commence employment, and subject to the
approval of our Board of Directors (the “Board”), NGM will grant you an option to purchase 250,000 shares of the Company’s common stock at the fair market value determined by the Board as of the date of grant (the “Option”).
The Option will be subject to the terms and 

 Aetna W. Wun, Ph.D. 

April 28, 2011 
  Page
 2
 
  

 
conditions of the Company’s Equity Incentive Plan (the “Plan”) and your grant agreement. Your grant agreement will reflect a four year vesting schedule, under which 25% of your
Option will vest after 12 months and 1/48th of the total will vest at the end of each month thereafter, until either the Option is fully vested or your employment ends, whichever occurs first. 

If, on or within eighteen (18) months after the effective date of a Change in Control (as defined below), NGM (or successor corporation) terminates your
employment without Cause (as defined below) and other than as a result of your death or disability, or you resign for Good Reason (as defined below), and provided such termination or resignation constitutes a “separation from service”
(within the meaning of Treasury Regulation Section 1.409A-1(h)), and you sign NGM’s standard form of release within the time period specified by NGM and allow it to become effective in accordance
with its terms but in no event later than 60 days following your termination, and provided you comply with your obligations under your Proprietary Information Agreement, then NGM will accelerate the vesting of the Option, to the extent
then-outstanding and unvested, such that the Option shall be deemed immediately vested and exerciseable as of your termination date. 
 For purposes of the
foregoing paragraph: (1) a “Change in Control” shall mean: (a) a sale of substantially all of the assets of NGM; (b) a merger or consolidation in which NGM is not the surviving corporation (other than a merger or
consolidation in which stockholders immediately before the merger or consolidation have, immediately after the merger or consolidation, a majority of the voting power of the surviving corporation); (c) a reverse merger in which NGM is the
surviving corporation but the shares of NGM’s Common Stock outstanding immediately preceding the merger are converted by virtue of the merger into other property, whether in the form of securities, cash or otherwise (other than a reverse merger
in which stockholders immediately before the merger have, immediately after the merger, a majority of the voting power of the surviving corporation); or (d) any transaction or series of related transactions in which 50% or more of NGM’s
voting power is transferred, other than the sale by NGM of stock in transactions the primary purpose of which is to raise capital for NGM’s operations and activities; (2) “Cause” shall mean (a) conviction of any felony or any
crime involving moral turpitude or dishonesty; (b) participation in a fraud or act of dishonesty against NGM; (c) willful and material breach of your duties that has not been cured within 30 days after written notice from your supervisor
of such breach; (d) intentional and material damage to NGM’s property; (e) material breach of the Proprietary Information Agreement; or (f) death, severe physical or mental disability; and (3) you shall have “Good
Reason” for your resignation from all positions held with NGM if any of the following actions are taken by NGM or a successor corporation or entity without your consent, and you notify NGM in writing, within ten (10) days after the
occurrence of one of the following actions, that you intend to terminate your employment no earlier than thirty (30) days after providing such notice, and NGM fails to cure such actions within thirty (30) days after receipt of such notice,
and such resignation is effective not later than (30) days after NGM fails to cure the issue; (a) a substantial reduction of your rate of compensation; (b) a material reduction in your duties; (c) a material failure or refusal of
a successor to NGM to assume NGM’s obligations under this letter in the event of a Change in Control; or (d) a relocation of your principal place of employment to a place greater than 50 miles from your then current principal place of
employment, which relocation results in a material increase in your commute. 
 NGM recognizes that the expenses associated with relocating can be high.
Therefore, to assist with your transition, the Company will pay for all reasonable and customary relocation expenses related to your move from Basel to the Bay Area, up to a maximum of $30,000.00 in the aggregate. This will include the cost of
moving, storage and temporary accommodation in the Bay Area. We take advantage of the most tax-effective method to relocate you, but please note that certain relocation expenses reimbursed to you or paid on
your behalf may be subject to federal and state income tax. You are responsible for all income tax obligations. 

 Aetna W. Wun, Ph.D. 

April 28, 2011 
  Page
 3
 
  

 As a condition of your employment, you will be required to abide by the Company’s policies and
procedures, including those outlined in our employee handbook. You also agree to read, sign and comply with the Company’s Employee Proprietary Information and Inventions Agreement (“Proprietary Information Agreement”). 

In your work for the Company, you will be expected to not make any unauthorized use of, or disclose, the confidential information or materials, including
trade secrets, of any former employer or other third party to whom you owe an obligation of confidentiality. Rather, you will be expected to use only that information generally known and used by persons with training and experience comparable to
your own, which information is common knowledge in the industry or otherwise legally available in the public domain, or which is otherwise provided or developed by the Company. By accepting employment with the Company, you are representing to us
that you will be able to perform your duties within the guidelines described in this paragraph. You represent further that you have disclosed to the Company any contract you have signed that may restrict your activities on behalf of the Company in
any manner. 
 This offer is contingent upon our verification of your employment history. Any intentional misrepresentation concerning your employment
history may result in actions up to and including revocation of this offer or termination of your employment at NGM. 
 Your employment relationship is at-will. Accordingly, you may terminate your employment with the Company at any time and for any reason whatsoever simply by notifying the Company. Likewise, the Company may terminate your employment at any time and
for any reason, with or without cause or advance notice. 
 This letter, together with your Proprietary Information Agreement, forms the complete and
exclusive statement of your agreement with the Company concerning this offer. The terms of this letter supersede any other representations or agreements made to you by any party, whether oral or written. The terms of our agreement cannot be changed
(except those changes expressly reserved to the Company’s discretion in this letter) other than by a written agreement signed by you and a duly authorized officer of the Company. This agreement is to be governed by the laws of the state of
California without reference to its conflicts of law principles. In case any provision contained in this agreement shall, for any reason be held invalid or unenforceable in any respect, such invalidity or unenforceability will not affect the other
provisions of this agreement, and such provision will be construed and enforced so as to render it valid and enforceable consistent with the general intent of the parties insofar as possible under applicable law. With respect to the enforcement of
this agreement, no waiver of any right hereunder will be effective unless it is in writing. This agreement may be executed in more than one counterpart, and signatures transmitted electronically will be deemed equivalent to originals. As required by
law, this offer is subject to satisfactory proof of your identity and right to work in the United States. 
 If you wish to accept employment at the Company
under the terms described above, please sign and date this letter and the Proprietary Information Agreement, and return them to me by April 29, 2011. 

 Aetna W. Wun, Ph.D. 

April 28, 2011 
  Page
 4
 
  

 NGM is an ambitious undertaking, and we fully expect our Company to become a force in the development and
commercialization of pharmaceutical therapies. To this end, we are assembling a team of uniquely qualified individuals with extraordinary knowledge, skills and drive. We look forward to your acceptance and to a productive and enjoyable working
relationship. 
  

	
	Sincerely,
	
	/s/ William J. Rieflin
	William J. Rieflin
	Chief Executive Officer

 Exhibit A – Employee Proprietary Information and Inventions Agreement 

Understood and Accepted: 
  

							
	 /s/ Aetna W. Wun
	  		  	 28 APR 2011
	  	
	Aetna W. Wun, Ph.D.	  		  	Date

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00287-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00287-of-00352.parquet"}]]